Kamini Jakhar, Sudipta Sonar, Gagandeep Singh, Tejeswara Rao Asuru, Garima Joshi, Nisha Beniwal, Tania Sarkar, Mahima Tiwari, Jaskaran Kaur, Deepak Kumar Rathore, Banwari Lal, Sandeep Kumar, Puneet Srivastav, Satendra Kumar, Vikas Phagna, Sushma Mithina, Lokesh Kumar, Vishal Gupta, Pallavi Kshetrapal, Savita Singh, Nitya Wadhwa, Ramachandran Thiruvengadam, Sreevatsan Raghavan, Mudita Gosain, Tripti Shrivastava, Sankar Bhattacharyya, Shailendra Asthana, Prasenjit Guchhait, Shailendra Mani
The presence of non-neutralizing antibodies of any dengue serotype increases the severity of subsequent infection by other dengue serotypes. During the SARS-CoV-2 pandemic, the number of symptomatic dengue cases increased in India. We found that antibodies isolated from convalescent plasma from COVID-19 patients enhances DENV2 infection in vitro . CR3022, an antibody against the SARS-CoV-2 spike protein, also elevated DENV2 infection in vitro . In silico protein–protein interactions between spike antibodies and the DENV2 E-protein revealed significant interactions. Likewise, few monoclonal/polyclonal antibodies against SARS-CoV-2 have shown increased dengue infection in vitro . Importantly, AG129 mice infected with SARS-CoV-2 three weeks prior to DENV2 infection showed elevated dengue pathogenesis. This highlights the possibility of elevated infection and symptomatic dengue disease in COVID-19 survivors.